[go: up one dir, main page]

HUP0103714A2 - Hipoglikémiás és hipolipidémiás hatással rendelkező oxiiminoalkánsavszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

Hipoglikémiás és hipolipidémiás hatással rendelkező oxiiminoalkánsavszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0103714A2
HUP0103714A2 HU0103714A HUP0103714A HUP0103714A2 HU P0103714 A2 HUP0103714 A2 HU P0103714A2 HU 0103714 A HU0103714 A HU 0103714A HU P0103714 A HUP0103714 A HU P0103714A HU P0103714 A2 HUP0103714 A2 HU P0103714A2
Authority
HU
Hungary
Prior art keywords
group
optionally
optionally substituted
hypoglycemic
acid derivatives
Prior art date
Application number
HU0103714A
Other languages
English (en)
Inventor
Hiroshi Imoto
Hiroyuki Kimura
Yu Momose
Hiroyuki Odaka
Junichi Sakamoto
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Publication of HUP0103714A2 publication Critical patent/HUP0103714A2/hu
Publication of HUP0103714A3 publication Critical patent/HUP0103714A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány szerinti vegyületek (I) általános képletében R1 jelentéseadott esetben szubsztituált szénhidrogéncsoport vagy adott esetbenszubsztituált heterociklusos csoport, X jelentése közvetlen kötés, -CO-, -CH(OH)- vagy -NR6- képletű csoport, ahol R6 jelentésehidrogénatom, adott esetben szubsztituált alkilcsoport, n értéke 1-3,Y jelentése oxigénatom, kénatom, -SO-, -SO2- vagy -NR7- képletűcsoport, ahol R7 jelentése hidrogénatom vagy adott esetbenszubsztituált alkilcsoport, A jelentése benzolgyűrű, amely adottesetben egy-három további szubsztituenssel szubsztituálva van, pértéke 1-8, R2 jelentése hidrogénatom, adott esetben szubsztituáltszénhidrogéncsoport vagy adott esetben szubsztituált heterociklusoscsoport, q értéke 0-6, m értéke 0 vagy 1, R3 jelentésehidroxilcsoport, -OR8 általános képletű csoport, ahol R8 jelentéseadott esetben szubsztituált szénhidrogéncsoport, A találmány kiterjeda vegyületeket tartalmazó gyógyszerkészítményekre és ezekalkalmazására diabetes mellitus, hiperlipemia, arteriosclerosismegelőzésénél. Ó
HU0103714A 1998-05-11 1999-05-10 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use HUP0103714A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12792298 1998-05-11
JP12792198 1998-05-11
PCT/JP1999/002407 WO1999058510A1 (en) 1998-05-11 1999-05-10 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Publications (2)

Publication Number Publication Date
HUP0103714A2 true HUP0103714A2 (hu) 2002-01-28
HUP0103714A3 HUP0103714A3 (en) 2003-05-28

Family

ID=26463748

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103714A HUP0103714A3 (en) 1998-05-11 1999-05-10 Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use

Country Status (27)

Country Link
US (3) US6251926B1 (hu)
EP (2) EP1428531A1 (hu)
JP (1) JP2000198772A (hu)
KR (1) KR100388120B1 (hu)
CN (1) CN1148361C (hu)
AR (1) AR029876A1 (hu)
AT (1) ATE272625T1 (hu)
AU (1) AU766831B2 (hu)
BR (1) BR9910371A (hu)
CA (1) CA2331879A1 (hu)
CO (1) CO5040066A1 (hu)
DE (1) DE69919156T2 (hu)
ES (1) ES2226377T3 (hu)
HK (1) HK1034972A1 (hu)
HU (1) HUP0103714A3 (hu)
ID (1) ID28699A (hu)
IL (1) IL139470A0 (hu)
LV (1) LV12606B (hu)
MY (1) MY123337A (hu)
NO (1) NO317426B1 (hu)
NZ (1) NZ508066A (hu)
PE (1) PE20000625A1 (hu)
PL (1) PL344002A1 (hu)
PT (1) PT1077957E (hu)
RU (1) RU2213738C2 (hu)
SK (1) SK16412000A3 (hu)
WO (1) WO1999058510A1 (hu)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508066A (en) * 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
AU7073400A (en) * 1999-08-27 2001-03-26 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
DE19948126A1 (de) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock
AU7958000A (en) * 1999-10-29 2001-05-14 Takeda Chemical Industries Ltd. Process for the preparation of oxyiminoalkanoic acid derivatives
AR031078A1 (es) 1999-10-29 2003-09-10 Takeda Pharmaceutical Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima.
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
WO2001034579A1 (fr) * 1999-11-10 2001-05-17 Takeda Chemical Industries, Ltd. Derives d'acide alcoxyiminoalcanoique
IL149493A0 (en) 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
EP1277730A4 (en) * 2000-03-28 2005-03-16 HEMMER OF NEOVASCULARIZATION
EP1310494B1 (en) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
EP1394154A4 (en) 2001-03-23 2005-05-18 Takeda Pharmaceutical FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE
CA2445322C (en) * 2001-04-25 2011-06-14 Takeda Chemical Industries, Ltd. Use of the abc expression promoting agent pioglitazone for the treatment of arteriosclerosis obliterans
EP1790353A1 (en) * 2001-12-29 2007-05-30 Novo Nordisk A/S Combined use of a GLP-1 compound and a modulator of diabetic late complications
TWI343915B (en) * 2002-10-07 2011-06-21 Hoffmann La Roche Chirale ppar agonists
AU2003278929A1 (en) * 2002-10-18 2004-05-13 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
WO2004053103A2 (en) * 2002-12-11 2004-06-24 University Of Massachusetts METHOD OF INTRODUCING siRNA INTO ADIPOCYTES
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
CN100438911C (zh) * 2002-12-27 2008-12-03 武田药品工业株式会社 体重增加抑制剂
AU2003266526A1 (en) * 2003-09-17 2005-04-11 Kaname Kawasugi Medicinal composition
CN1922135B (zh) * 2004-02-24 2011-07-06 Irm责任有限公司 免疫抑制剂化合物和组合物
CA2560928A1 (en) * 2004-03-29 2005-10-06 Sankyo Company Limited Therapeutic agent for diabetes containing insulin resistance improving agent
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
EP1790338A4 (en) * 2004-09-13 2007-12-12 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT FOR KERATOCONJUNTIVA DISEASES
US7556933B2 (en) * 2004-10-01 2009-07-07 Luminultra Technologies Ltd. Reagent system and process for adenosine triphosphate monitoring
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
EP1876179B1 (en) 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
WO2006126514A1 (ja) 2005-05-27 2006-11-30 Shionogi & Co., Ltd. イソキサゾール骨格を有するアリール酢酸誘導体
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US7491414B2 (en) * 2005-10-12 2009-02-17 Gaia Herbs, Inc. Anti-inflammatory substances extracted from Echinacea
EP2149550A4 (en) 2007-04-27 2010-08-11 Takeda Pharmaceutical NITROGENIC FIVE-GLOSS HETEROCYCLIC COMPOUND
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP2322222A4 (en) 2008-08-07 2011-12-21 Takeda Pharmaceutical THERAPEUTIC FOR IRRITATION SYNDROME
WO2010064147A2 (en) 2008-12-04 2010-06-10 Ikfe Gmbh Biomarkers for atherosclerosis
AU2009325962A1 (en) 2008-12-11 2011-07-28 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for insulin sensitizer drug response
EP2382467A1 (en) 2008-12-30 2011-11-02 IKFE GmbH Biomarkers for adipose tissue activity
US20100210541A1 (en) 2009-01-07 2010-08-19 Andreas Pfuetzner Biomarkers for Appetite Regulation
CN102875548A (zh) * 2011-07-14 2013-01-16 中国科学院大连化学物理研究所 一类基于肟的通过[2+2+2]环加成合成吡啶衍生物的方法
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
EA027451B1 (ru) 2011-08-30 2017-07-31 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
ES2716151T3 (es) 2013-09-30 2019-06-10 Ono Pharmaceutical Co Compuesto que tiene actividad agonista del receptor de somatostatina y uso farmacéutico del mismo
EP3083587B1 (en) * 2013-12-16 2018-04-04 Cadila Healthcare Limited Oximino derivatives for the treatment of dyslipidemia
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
FR3042903B1 (fr) * 2015-10-21 2017-12-08 Commissariat Energie Atomique Utilisation d'acides hydroxyiminoalcanoiques comme agents anti-nitreux dans des operations de desextraction reductrice du plutonium
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
TW201835081A (zh) 2017-02-08 2018-10-01 日商小野藥品工業股份有限公司 具有體抑素受體促效活性之化合物及其醫藥用途
US11109683B2 (en) 2019-02-21 2021-09-07 Steelcase Inc. Body support assembly and method for the use and assembly thereof
US11357329B2 (en) 2019-12-13 2022-06-14 Steelcase Inc. Body support assembly and methods for the use and assembly thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177578B (en) 1976-08-27 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing new 0-/3-amino-2-hydroxy-propyl/-amidoxime derivatives
JPS5849382A (ja) 1981-09-18 1983-03-23 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS59167576A (ja) 1983-03-15 1984-09-21 Kyowa Hakko Kogyo Co Ltd β−ラクタム化合物
JPS6277391A (ja) 1984-12-21 1987-04-09 Mochida Pharmaceut Co Ltd セフアロスポリン誘導体、その製法およびそれらを有効成分とする抗菌剤
JPS62158290A (ja) * 1985-12-28 1987-07-14 Banyu Pharmaceut Co Ltd 新規セフアロスポリン誘導体
US4698338A (en) 1986-02-19 1987-10-06 Eli Lilly And Company 7[2-(2-aminothiazol-4-yl)-2-benzyloximino]acetamido-3[4-alkyl-5-oxo-6-hydroxy-3,4-dihydro-1,2,4-triazin-3-yl]thiomethyl cephalosporins
US5750532A (en) * 1986-12-10 1998-05-12 Schering Corporation Pharmaceutically active compounds
JPH0277391A (ja) 1988-09-14 1990-03-16 Suzuki Motor Co Ltd 水ジェット推進船のビルジ水排水装置
DE68928783T2 (de) 1988-11-21 1998-12-24 Zeneca Ltd., London Zwischenverbindungen zur Herstellung von Fungiziden
EP0400805A1 (en) 1989-04-25 1990-12-05 Toshiyasu Ishimaru Cephalosporin compounds and their use
JPH03115272A (ja) * 1989-10-19 1991-05-16 Banyu Pharmaceut Co Ltd マンデル酸誘導体およびその製法
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
ES2110421T5 (es) * 1990-06-27 2004-12-01 Basf Aktiengesellschaft O-bencil-oximeteres y los agentes protectores de las plantas que contienen estos compuestos.
JPH04112890A (ja) * 1990-09-04 1992-04-14 Ajinomoto Co Inc 新規チアゾール誘導体及び該誘導体を含有する抗菌剤
EP0486011A3 (en) * 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
KR100191137B1 (ko) 1992-07-21 1999-06-15 사노 가즈오 옥심 유도체
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
US5703096A (en) 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
CH689228A5 (de) 1994-10-07 1998-12-31 Novartis Ag Oximether, sowie diese enthaltende Pflanzenschutzmittel.
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
AU5701896A (en) * 1995-06-02 1996-12-18 Sankyo Company Limited Aromatic oxyimino derivatives
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
FR2737893B1 (fr) * 1995-08-16 1997-09-12 Roussel Uclaf Nouvelles cephalosporines comportant en position 7, un radical benzyloxyimino substitue, leur procede et intermediaires de preparation, leur application comme medicaments
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JPH09323929A (ja) 1996-04-02 1997-12-16 Sankyo Co Ltd オキシム誘導体を含有する医薬
NZ332136A (en) 1996-04-04 1999-08-30 Sankyo Co Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
WO1998005331A2 (en) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
JPH11193272A (ja) 1997-10-01 1999-07-21 Sankyo Co Ltd フェニルアルキルカルボン酸誘導体を含有する医薬
NZ508066A (en) * 1998-05-11 2003-03-28 Takeda Chemical Industries Ltd Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

Also Published As

Publication number Publication date
US20030186985A1 (en) 2003-10-02
ATE272625T1 (de) 2004-08-15
IL139470A0 (en) 2001-11-25
EP1077957A1 (en) 2001-02-28
AR029876A1 (es) 2003-07-23
JP2000198772A (ja) 2000-07-18
ES2226377T3 (es) 2005-03-16
NO20005531D0 (no) 2000-11-02
LV12606A (lv) 2001-01-20
CN1148361C (zh) 2004-05-05
HUP0103714A3 (en) 2003-05-28
KR100388120B1 (ko) 2003-06-18
PT1077957E (pt) 2004-10-29
AU3629799A (en) 1999-11-29
EP1428531A1 (en) 2004-06-16
DE69919156D1 (de) 2004-09-09
NO317426B1 (no) 2004-10-25
US6251926B1 (en) 2001-06-26
KR20010021523A (ko) 2001-03-15
CO5040066A1 (es) 2001-05-29
MY123337A (en) 2006-05-31
SK16412000A3 (sk) 2001-08-06
US6924300B2 (en) 2005-08-02
CA2331879A1 (en) 1999-11-18
RU2213738C2 (ru) 2003-10-10
NO20005531L (no) 2001-01-05
LV12606B (en) 2001-05-20
AU766831B2 (en) 2003-10-23
PL344002A1 (en) 2001-09-10
CN1300285A (zh) 2001-06-20
ID28699A (id) 2001-06-28
EP1077957B1 (en) 2004-08-04
US6495581B1 (en) 2002-12-17
NZ508066A (en) 2003-03-28
WO1999058510A1 (en) 1999-11-18
DE69919156T2 (de) 2005-11-03
BR9910371A (pt) 2001-01-09
HK1034972A1 (en) 2001-11-09
PE20000625A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
HUP0103714A2 (hu) Hipoglikémiás és hipolipidémiás hatással rendelkező oxiiminoalkánsavszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0203165A2 (hu) Nitrogént tartalmazó, öttagú heterociklusos vegyületek
HUP0202251A2 (hu) Heterociklust tartalmazó bifenil aP2 inhibitorok és alkalmazásuk
HUP0102556A2 (hu) Benzolszulfonamidszármazékok és felhasználásuk gyógyszerkészítményként és eljárás a vegyületek előállítására
DE69231886D1 (de) Thiazolidindionderivate, herstellung und anwendung
HUP0102470A2 (hu) Retinoidrokon receptorok funkcióját szabályozó 1,3-azol-származékok és alkalmazásuk
NZ284654A (en) Oxazolyl substituted 3,5-dioxo-oxadiazolidine or 2,4-dioxo-thiazolidine derivatives and medicaments
DK165109C (da) 4-anilino-cyklopentaoedaapyrimidinderivater samt farmaceutiske midler indeholdende saadanne
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
DE69222459D1 (de) Thiazolidindionderivate, ihre Herstellung und Anwendung
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0001858A2 (hu) Biaromás vegyületek, ezeket tartalmazó gyógyászati és kozmetikai készítmények, valamint e vegyületek alkalmazása
ATE104278T1 (de) N-substituierte alpha-mercaptoalkylaminderivate, verfahren zu ihrer herstellung und hergestellte zwischenprodukte, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen.
KR920007995A (ko) 벤즈아미드 유도체
DK0452204T3 (da) Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE69621712D1 (de) Arylpiperidin- und Arylpiperazin-Derivate und sie enthaltende Arzneimittel
ATE275572T1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
DE3780191D1 (de) Octahydroindolizine analgesica und 7-keto-zwischenprodukte.
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
FI860074A (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
EP0487996B1 (de) 3-substituierte Cephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2003082854A1 (fr) Derives 1-n-aminobenzimidazole
PT805155E (pt) Novo composto heterociclico condensado, anti-oxidante triciclico
IE43338L (en) Pharmaceutical composition
HUP9903813A2 (hu) Ditiazol-dioxidok és mikrobicidként történő alkalmazásuk

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees